PA
GYRE icon

Parallel Advisors’s Gyre Therapeutics GYRE Stock Holding History

Parallel Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15
Closed -$182 – 3576
2024
Q4 		$182 Buy
+15
New +$192 ﹤0.01% 3391

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Parallel Advisors's GYRE Position: Q1 2025 in Review

Parallel Advisors sold out of Gyre Therapeutics (GYRE) in Q1 2025, closing a stake of 15 shares — an estimated $182 sold.

Parallel Advisors first reported a position in GYRE in Q4 2024 and held it in 1 quarter. The position peaked at $182 in Q4 2024. 46 funds tracked by Wall St. Rank hold GYRE as of Q1 2025.

  • Parallel Advisors reported no remaining Gyre Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Parallel Advisors sold 15 Gyre Therapeutics shares in Q1 2025, an estimated $182.
  • Parallel Advisors first reported a position in Gyre Therapeutics in Q4 2024 and held it in 1 quarter.
  • Parallel Advisors's Gyre Therapeutics position peaked at $182 in Q4 2024.
  • 46 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2025.

Based on Parallel Advisors's 13F filing for Q1 2025, filed 8 Apr 2025.